Lynn is CEO and founder of STALICLA. Driven by her lifelong involvement in the autism community, she co-developed DEPI, Stalicla algorithm to advance precision medicine in autism spectrum disorder. A biotech entrepreneur, Lynn has extensive experience in Business Development. She previously worked for the World Economic Forum, a leading Swiss venture capital firm, and start-up accelerators in Western Switzerland. She also spent 5 years at the University of Geneva Faculty of Medicine. Lynn holds Master degrees in political sciences and economic history, and corporate communication. She is finalizing a post-graduate degree in drug discovery and clinical development at the University of Geneva Faculty of Medicine.
Benjamin is the Global Head of Overlay Management at Edmond de Rothschild Asset Management Suisse and a member of the enlarged executive committee of EDRAM. He holds a Post-Graduate Master’s Degree in Engineering, IT and Mathematics and a Masters in Finance from ESSEC business school.
Hugo Ferreira is Director of Huniel Conseil S.A.(created in 2014) in Geneva. He joined in 1991 La Compagnie Benjamin de Rothschild S.A.as Deputy General Manager until end of 2013. He has an extensive experience in finance (finance director, treasurer, structuring loan department, corporate finance), working for well-known institutions such as Nestlé (Switzerland and the USA), Citicorp Investment Bank (New York), as well as the Group Tradition. He is a non-executive director of Cobepa and several Private Equity funds.
Hugo is a commercial engineer from the Solvay School (Université Libre de Bruxelles) and holds a MBA from Columbia University (New York).
Dr. Guillaume Pfefer is currently CEO-Partner at Flagship Pioneering and also serves as Chief Executive Officer at Senda Biosciences. Over the last 25 years he gathered a broad range of experiences in executive roles in Blue-Chip pharma as well as start-up biotechs. As SVP, Global Vaccine Leader Shingrix at GSK, he achieved the best biopharma launch in the US over the last decade and grew Shingrix revenues to 2.3b$. Under his leadership between 2012 and 2014, Kala Pharmaceuticals transformed from a pre-clinical technology platform start-up to a leading publicly-traded ophthalmology company.
Guillaume is a Chemical Engineer, and holds a PhD in Materials Science from Centre National de la Recherche Scientifique (CNRS), France, and an MBA, from the Wharton School at the University of Pennsylvania.
Dr. Otto Schwarz is a highly accomplished industry veteran. He brings significant operational and commercial leadership experience through the positions he occupied as Actelion’s Chief Operating Officer, Executive Vice-President, and member of the Executive Committee - until Actelion’s notable acquisition by Johnson and Johnson in 2017.
Otto holds a Ph.D. in Pharmaceutical Chemistry from the University of Vienna and a Post-Doc from the University of Florida.
Jacques Bonvin is Partner at Tavernier Tschanz. After training mainly in international commercial arbitration and litigation, Jacques Bonvin has specialized over the last twenty years, and is now active in corporate law, international mergers and acquisitions and corporate finance, including private equity and venture capital, with a special emphasis on the technology and biotechnology sector. Jacques Bonvin regularly advises board of directors on corporate governance and strategic issues.